<DOC>
	<DOCNO>NCT00038961</DOCNO>
	<brief_summary>This multicentre , randomize , double-blind , placebo control study . During study patient receive background venous thromboembolism ( VTE ) mechanical prophylaxis intermittent pneumatic compression ( IPC ) .</brief_summary>
	<brief_title>A Study Evaluate Efficacy Safety Fondaparinux Sodium When Used With Intermittent Pneumatic Compression Prevent Venous Thromboembolic ( IPC ) Versus IPC Alone Prevention Venous Thromboembolic Events Subjects Increased Risk Undergoing Major Abdominal Surgery ( APOLLO ) .</brief_title>
	<detailed_description>This multicenter , randomize , double-blind , placebo-controlled study evaluate safety efficacy fondaparinux prevention venous thromboembolism ( VTE ) subject undergoing abdominal surgery increase risk VTE . During study subject receive background VTE prophylaxis intermittent pnuematic compression ( IPC ) ± elastic stocking ( ES ) . Screening Period ( Day -30-Day 0 ) subject increase risk VTE undergo abdominal surgery fulfil study entry criterion eligible study . Treatment Period ( Day 7 ±2 ) : At baseline assessment day surgery ( Day 1 ) subject satisfy inclusion/exclusion criterion randomize ( 1:1 ) receive either fondaparinux placebo . All subject receive background therapy IPC ±ES . The first administration either fondaparinux 2.5mg placebo take place 6 8 hour surgical closure provide hemostasis achieve . Thereafter daily subcutaneous injection either fondaparinux 2.5mg placebo administer Day 7 ±2 . During treatment phase , subject assess daily . A mandatory venogram perform Day 5 10 early case symptomatic VTE , 1 calendar day last study treatment administration . Follow Period ( Day 30 ±2 ) : A follow-up visit contact take place Day 30 ±2 day . Use antithrombotic therapy prevention VTE mandatory venographyand entire Follow-up Period leave investigator 's discretion .</detailed_description>
	<mesh_term>Thromboembolism</mesh_term>
	<mesh_term>Fondaparinux</mesh_term>
	<mesh_term>PENTA</mesh_term>
	<criteria>Undergoing abdominal surgery ( surgery diaphragm pelvic floor ) lasting longer 45 minute ( duration anesthesia induction surgical closure ) Over 40 year age Subject sign informed consent . Active , clinically significant bleeding Documented congenital acquire bleed tendency/disorders Active ulcerative gastrointestinal disease unless reason present surgery . Recent intracranial hemorrhage recent ( less 3 month prior randomisation ) brain , spinal , ophthalmologic surgery . Indwelling intrathecal epidural catheter 6 hour surgical closure . Subjects traumatic puncture unusual difficulty apply catheter Known cerebral metastasis , Subjects hemostasis establish 6 hour surgical closure , Current thrombocytopenia , Bacterial endocarditis Creatinine level 2.0 mg/dL ( 180 μmol/L ) wellhydrated subject , Documented hypersensitivity contrast medium , Use contraindicate drug could combine injection contrast medium , Patent evidence leg ischemia cause peripheral vascular disease , unable undergo IPC unable wear Elastic Stockings . Exclusion criterion related trial methodology : Mental disorder could interfere study participation and/or failure give write informed consent take part study , Subject 's life expectancy &lt; 6 month , Clinical sign DVT and/or history recent DVT , Participation therapeutic drug study device study evaluate DVT prophylaxis within 90 day precede inclusion , Previous participation study fondaparinux sodium , Known hypersensitivity fondaparinux excipients , Current addictive disorder could interfere study participation , Administration heparin , heparinoids , LMWH , oral anticoagulant , dextrans , hirudin , fibrinolytic agent drug block glycoprotein platelet receptor ( GPIIbIIIa ) screen period , i.e. , admission surgery , Subjects anticoagulant therapy contraindicate , due concomitant disease , indication oral anticoagulant heparin ( include LMWH ) could discontinue treatment , Women childbearing potential : woman use appropriate contraceptive method whole duration study participation , Subject body weight &lt; 50 kg , Subjects , opinion investigator , require pharmacological prophylaxis addition intermittent pneumatic compression , Known pregnancy / woman intend breastfeed , Subjects undergoing vascular surgery aortofemoral bypass graft</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>fondaparinux sodium</keyword>
	<keyword>DVT Prevention</keyword>
	<keyword>abdominal surgery</keyword>
	<keyword>VTE prevention</keyword>
	<keyword>venous thromboembolism</keyword>
	<keyword>pulmonary embolism</keyword>
</DOC>